期刊文献+

首次使用氯丙嗪和利培酮对精神分裂症患者血糖代谢的影响 被引量:3

The metabolism of blood glucose affected by chlorpromazine and risperidal in first treatment of patients with schizophrenia.
下载PDF
导出
摘要 目的探讨首次使用氯丙嗪和利培酮对精神分裂症患者血糖代谢的影响。方法114例住院精神分裂症患者随机分为氯丙嗪组和利培酮组。治疗前及治疗后第1、2、3、6个月及12个月后分别测定多项血糖指标浓度,并进行对照分析。结果治疗3个月时的空腹血糖(FPG)、2小时糖耐量(2HPG)及餐后2小时血糖(2HPBG),以及治疗6个月时的糖化血红蛋白(HbA lc)浓度明显高于治疗前;治疗12个月后有15.79%的患者发生血糖调节功能受损(IGR),其中氯丙嗪组为11.65%,明显高于利培酮组6.32%;随着精神病发病年龄的增长,上述血糖浓度也逐步提高;发病年龄、疗前糖耐量及脂蛋白β浓度接近正常上限可能是IGR的诱因。结论首次使用氯丙嗪和利培酮即可影响糖代谢,应早期监测血糖,早期干预。 Objective To study the metabolism of blood glucose affected by chlorpromazine and risperidal in first treatment of patients with schizophrenia. Methods 114 schizophrenia inpatients who first use antipsychotics were randomly treated by chlorpromazine and risperidal with single medication, and were tested blood glucose at the admission, one, two, three,six months and one year after treatment respectively to contrast;Results FPG,2HPG,2HPBG,at three months and HbAic at six months after treatment were siglnificantly higher than before treatment. IGR occurred in 15.79% subjects one year after treatment. The occurrence of IGR in group chlorpromazine( 11.65% )was siglnificantly higher than in group risperidal(6.32% ). With the growth age of onset of psychosis, blood glucose concentrations above-mentioned also raised gradually. Age of onset,glucose tolerance before threatment and lipoprotein B close to upper normal limit may be inducements of IGR. Conclusion Chlorpromazine and risperidal may impact the metabolism of blood glucose in first treatment, so blood glucose should be follow up initially,with PBG in particular.
作者 袁杰 瞿正万
出处 《四川精神卫生》 2006年第4期197-199,共3页 Sichuan Mental Health
关键词 氯丙嗪 利培酮 血糖 血糖调节功能受损(IGR) Chlorpromazine Risperidal Blood glucose Impaired-glucose-regulation(ICR)
  • 相关文献

参考文献5

  • 1叶任高 陆再英.内科学[M].北京:人民卫生出版社,2002.216.
  • 2Hagg S,Joelsson L,Mjorndal T,et al.Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with convertional depot neuroleptic medications.J Clin Psychiatry,1998,59(2):294.
  • 3刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平、利培酮对精神分裂症病人血糖-胰岛素稳态的影响及相关因素分析[J].上海精神医学,2003,15(5):257-259. 被引量:33
  • 4Wang PS,Glynn RJ,Gana DA,et al.Clozapine use and risk of diabetes mellitus.J Clin Psychopharmacol,2002,22 (3):236~243.
  • 5Harris MI,Flegal KM,Cowie CC,et al.Prevalence of diabetes,impaired fasting glucose,and impaired glucose tolerance in U.S.Adultes.The Third National Health and Nutrition Examinastion Survey,1994.Diabetes Care,1998,21:518~524.

二级参考文献13

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 2[1]Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry, 2000, 157(6) : 975 ~981
  • 3[2]Ghaeli D, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy, 1999,19(9) : 1099~1101
  • 4[3]Leadbetter R , Shutty M , Pavalonis D , et al . Clozapine - induced weight gain: prevalence and clinical relevance. Am J Pchiatry,1992, 149 : 68 ~72
  • 5[4]Melksson K, Hulting AL. Antipsychotic drugs can affect hormone balance. Weight gain, blood lipid disturbances and diabetes are important. Lakartininger, 2001,98(48) : 5462 ~5464
  • 6[5]Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care, 1997, 20: 1087 ~ 1092
  • 7[7]Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985,28 : 412 ~419
  • 8[9]Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol, 2002, 22 (3) : 236 ~ 243
  • 9[12]Sowell MO, Makhopadkyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone or placebo. J Clin Endocrinol Metab, 2002, 87(6) : 2918 ~2923
  • 10[13]Baptista T, Lacruz A, Angeles F, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry, 2001,34(6) : 223 ~ 231

共引文献235

同被引文献21

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部